Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AVArx vs LVNG RX

AVArx
Graded #426

Lower grade

vs+6.600000000000001
LVNG RX
Graded #268

Higher grade

The verdict

LVNG RX takes it — 62.5/100 to 55.9/100.

LVNG RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LVNG RX is a Delaware-registered telehealth platform (LVNG RX LLC) offering compounded semaglutide from $149/mo and tirzepatide from $249/mo, plus a lower-dose GLP-1 microdose program.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLVNG RX +19
45
64
Dose & formulationLVNG RX +24
40
64
Clinical oversightAVArx +21
77
56
Labs & monitoringLVNG RX +10
52
62
FulfillmentAVArx +16
85
69
Contract termsLVNG RX +20
41
61
AVArx · left barLVNG RX · right bar

The numbers

MetricAVArxLVNG RX
WeighScore55.9/10062.5/100
GradeCC
Scorecard rank#426#268
SemaglutideNot disclosed$149/mo (starting dose, compounded)
TirzepatideNot disclosed$249/mo (microdose tier, starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AVArx

Graded #426 · C

Strengths

  • Publishes exactly which states require a live audio or video visit before a prescription, which almost no competitor discloses
  • Names its prescribing group, Arora Health & Aesthetics, and gives a medical compliance contact
  • Terms state service is available to residents of all 50 states, and the shipping policy matches
  • Dates its own editorial reviews on treatment pages
  • HSA/FSA accepted with receipts provided for reimbursement

Where it loses points

  • No price is published anywhere on the site, on treatment pages or in the intake, so you cannot compare before starting a visit
  • Never states whether its semaglutide and tirzepatide are compounded or brand-name
  • No dispensing pharmacy is named, only licensed pharmacies in our network
  • Cancellation terms are not published, only presented at checkout
  • Prescriptions cannot be returned once dispensed, and the refund policy is otherwise unstated
LVNG RX

Graded #268 · C

Strengths

  • One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
  • States you are charged nothing if a provider does not approve you for treatment
  • Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
  • Semaglutide from $149/mo is competitive against the wider compounded market
  • Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide

Where it loses points

  • Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
  • Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
  • Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
  • The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
  • No compounding pharmacy, medical group or individual clinician is named anywhere on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard